Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05725421 · ClinicalTrials.gov registry record · NA
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
A NA study of Renal Cell Carcinoma, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05725421: Recruiting NA study of Renal Cell Carcinoma, sponsored by Case Comprehensive Cancer Center.
NCT05725421 is a NA study of Renal Cell Carcinoma that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 5 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05725421, a NA study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts
Primary Outcome
Safety and feasibility as determined by peri-operative adverse events of the following Grade 3-5 CTCAE v5.0 outcomes within 30 days of surgery: i. Anemia ii. Acute kidney injury
Conditions Studied
Interventions
- PROCEDURE Donor Radical and Partial Nephrectomy
- PROCEDURE Kidney Transplantation
- PROCEDURE Laparoscopic Radical Nephrectomy
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT05725421 shows while recruiting
NCT05725421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Donor Radical and Partial Nephrectomy is the first listed.
NCT05725421 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05725421 about?
NCT05725421 is a clinical study titled "Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy". This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts
What is the current status of trial NCT05725421?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2023-09-08. Estimated completion is 2026-06.
What conditions does trial NCT05725421 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT05725421?
The interventions under investigation include: Donor Radical and Partial Nephrectomy (PROCEDURE), Kidney Transplantation (PROCEDURE), Laparoscopic Radical Nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT05725421?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05725421 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05725421's enrollment target sits among peer trials
5 121st of 121 the lowest of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
RECRUITING · NA
-
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
RECRUITING · NA
-
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
RECRUITING · NA
-
Evaluation of a Simple-Prep Controlled Embolic
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI